Synapse - Pedram Razavi

Results (175)

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Journal Article

Zehir, A.; Benayed, R.; Shah, R. H.; Syed, A.; Middha, S.; Kim, H. R.; Srinivasan, P.; Gao, J.; Chakravarty, D.; Devlin, S. M.; more...
Nature Medicine (2017)

Fulltext@MSK | Save

Analysis of CDH1 in invasive lobular carcinoma (ILC): Comparison of morphology, immunohistochemistry (IHC) and mutation profile detected by hybrid capture-based next generation sequencing (NGS)

Meeting Abstract

Grabenstetter, A.; Mohanty, A. S.; Zehir, A.; Razavi, P.; Baselga, J.; Tan, L. K.; Ross, D. S.
Modern Pathology (2017)

Fulltext@MSK | Save

Capturing genomic evolution of lung cancers through liquid biopsy for circulating tumor DNA

Journal Article

Offin, M.; Chabon, J. J.; Razavi, P.; Isbell, J. M.; Rudin, C. M.; Diehn, M.; Li, B. T.
Journal of Oncology (2017)

Fulltext@MSK | Save

Analysis of CDH1 in invasive lobular carcinoma (ILC): Comparison of morphology, immunohistochemistry (IHC) and mutation profile detected by hybrid capture-based next generation sequencing (NGS)

Meeting Abstract

Grabenstetter, A.; Mohanty, A. S.; Zehir, A.; Razavi, P.; Baselga, J.; Tan, L. K.; Ross, D. S.
Laboratory Investigation (2017)

Fulltext@MSK | Save

Activating ESR1 mutations differentially affect the efficacy of ER antagonists

Journal Article

Toy, W.; Weir, H.; Razavi, P.; Lawson, M.; Goeppert, A. U.; Mazzola, A. M.; Smith, A.; Wilson, J.; Morrow, C.; Wong, W. L.; more...
Cancer Discovery (2017)

Fulltext@MSK | Save

Next-generation assessment of human growth factor receptor 2 (ERBB2) amplification status: Clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay

Journal Article

Ross, D. S.; Zehir, A.; Cheng, D. T.; Benayed, R.; Nafa, K.; Hechtman, J. F.; Janjigian, Y. Y.; Weigelt, B.; Razavi, P.; Hyman, D. M.; more...
Journal of Molecular Diagnostics (2017)

Fulltext@MSK | Save

Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363)

Meeting Abstract

Smyth, L. M.; Reichel, J. B.; Tang, J.; Patel, J. A. A.; Meng, F.; Selcuklu, S. D.; You, D.; Samoila, A.; Schiavon, G.; Li, B. T.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Use of next generation sequencing and quantitative mass spectrometry to determine HER2 status

Meeting Abstract

Razavi, P.; Cecchi, F.; Ross, D. S.; Middha, S.; Zehir, A.; Arcila, M. E.; Hembrough, T. A.; Berger, M. F.; Scaltriti, M.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Systematic functional characterization of resistance to PI3K inhibition in breast cancer

Journal Article

Le, X.; Antony, R.; Razavi, P.; Treacy, D. J.; Luo, F.; Ghandi, M.; Castel, P.; Scaltriti, M.; Baselga, J.; Garraway, L. A.
Cancer Discovery (2016)

Fulltext@MSK | Save

PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition

Journal Article

Castel, P.; Ellis, H.; Bago, R.; Toska, E.; Razavi, P.; Carmona, F. J.; Kannan, S.; Verma, C. S.; Dickler, M.; Chandarlapaty, S.; more...
Cancer Cell (2016)

Fulltext@MSK | Save